22,550 Shares in Ocugen, Inc. (NASDAQ:OCGN) Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft purchased a new position in shares of Ocugen, Inc. (NASDAQ:OCGN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 22,550 shares of the company’s stock, valued at approximately $35,000.

Several other institutional investors also recently bought and sold shares of OCGN. Truefg LLC purchased a new position in Ocugen during the 1st quarter worth $34,000. David J Yvars Group purchased a new position in Ocugen during the 1st quarter worth $35,000. Headlands Technologies LLC purchased a new position in Ocugen during the 1st quarter worth $66,000. Tidal Investments LLC purchased a new position in Ocugen during the 1st quarter worth $108,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Ocugen during the 1st quarter worth $132,000. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

Ocugen Stock Up 2.3 %

OCGN stock traded up $0.03 on Thursday, hitting $1.31. 3,266,831 shares of the company’s stock were exchanged, compared to its average volume of 7,147,027. Ocugen, Inc. has a 12-month low of $0.35 and a 12-month high of $2.11. The firm has a 50 day moving average price of $1.52 and a two-hundred day moving average price of $1.37. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.87 and a current ratio of 1.87. The stock has a market cap of $337.13 million, a P/E ratio of -5.12 and a beta of 3.65.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Thursday, August 8th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $1.14 million for the quarter. During the same quarter last year, the business posted ($0.10) EPS. As a group, equities research analysts expect that Ocugen, Inc. will post -0.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OCGN has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Ocugen in a report on Wednesday, May 15th. Chardan Capital reiterated a “buy” rating and issued a $5.00 price target on shares of Ocugen in a report on Wednesday, May 15th.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.